Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05157958 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

A Phase 2 study of Dystrophic Epidermolysis Bullosa, sponsored by Anterogen Co..

Recruiting
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT05157958 is a Phase 2 study of Dystrophic Epidermolysis Bullosa that is actively recruiting participants, run by Anterogen Co.. The registered enrollment target is 6 participants, below the 20-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05157958, a Phase 2 study of Dystrophic Epidermolysis Bullosa, is actively recruiting participants, sponsored by Anterogen Co..

RECRUITING
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.

Conditions Studied

Dystrophic Epidermolysis Bullosa

Interventions

  • OTHER Vehicle Control
  • BIOLOGICAL ALLO-ASC-SHEET

Study Locations (1)

Florida

  • University of Miami Dermatology Clinical Trials Unit - Miami

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2023-05-01
Est. Completion 2026-04-28
Phase Phase 2

Sponsor

Anterogen Co.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05157958

The ClinicalTrials.gov registry entry for NCT05157958 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 20-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (70% lower). The listed sponsor is Anterogen Co., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Control is the first listed.

NCT05157958 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05157958 about?

NCT05157958 is a clinical study titled "Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa". After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the tim...

What is the current status of trial NCT05157958?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2023-05-01. Estimated completion is 2026-04-28.

What conditions does trial NCT05157958 study?

This clinical trial studies the following conditions: Dystrophic Epidermolysis Bullosa.

What interventions are being tested in trial NCT05157958?

The interventions under investigation include: Vehicle Control (OTHER), ALLO-ASC-SHEET (BIOLOGICAL).

Who is sponsoring clinical trial NCT05157958?

This trial is sponsored by Anterogen Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05157958 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dystrophic Epidermolysis Bullosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dystrophic Epidermolysis Bullosa

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.